Table 1.
Patient, disease, and treatment-related characteristics.
| Patient characteristics | |
| Age | 64 years (38–86) |
| Males | 22 (50%) |
| Females | 22 (50%) |
| ECOG | |
| 0 | 15 (34%) |
| 1 | 24 (55%) |
| 2 | 5 (11%) |
| Disease characteristics | |
| Number of lung nodules | 50 |
| Size | 1.3 cm (0.4–3.8) |
| Pre-SBRT SUV | 3.7 (0.6–12.2) |
| Extra-thoracic disease | 14 (34%) |
| Oligometastasis (<5 sites) | 39 (89%) |
| Primary Site | |
| Colorectal | 22 (50%) |
| Breast | 6 (13.5%) |
| Head and neck | 6 (13.5%) |
| Endometrial | 3 (7%) |
| Other* | 7 (16%) |
| Location | |
| Upper | 26 (59%) |
| Middle | 2 (4.5%) |
| Lower | 22 (50%) |
| Treatment characteristics | |
| Dose | 48 Gy in 5 Fx (36–54 Gy in 3–8 Fx) |
| Planning target volume | 12.92 cc (3.3–103 cc) |
| Chemotherapy prior to lung SBRT | 33 (75%) |
ECOG, Eastern Cooperative Oncology Group; SBRT, Stereotactic Body Radiotherapy; SUV, Standard uptake volume; Gy, Gray; Fx, Fractions; cc, cubic centimeter.
*
Includes renal (n = 2), thyroid (n = 1), bladder (n = 1), Ewing's (n = 1), cholangiocarcinoma (n = 1).